The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results Meeting Abstract
| Authors: | Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; Maccaro, C.; Blouin, W.; Schwieterman, J.; Cathcart, E.; Fang, S.; Perez, L.; Ryu, S.; Galasso, N.; Straus, D.; Fisher, D. C.; Kumar, A.; Noy, A.; Falchi, L.; Dogan, A.; Kim, Y. H.; Weinstock, D. |
| Abstract Title: | The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results |
| Meeting Title: | 16th International Conference on Malignant Lymphoma - Virtual Edition |
| Journal Title: | Hematological Oncology |
| Volume: | 39 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Jun 18-22 |
| Meeting Location: | Virtual |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-06-01 |
| Start Page: | 100 |
| End Page: | 101 |
| Language: | English |
| ACCESSION: | 150947588 |
| DOI: | 10.1002/hon.56_2879 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 34105791 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 56 - Accession Number: 150947588 -- Entry Date: In Process -- Revision Date: 20210618 -- Publication Type: Article -- Supplement Title: Jun2021 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: Cinahl |
